Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2011
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://ncbi.nlm.nih.gov/pubmed/21540861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.151
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge